ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs—CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate (ADC) ALX2004—during a presentation at the J.P.
Despite HCM’s strong genetic basis, patients residing in lower-income or more socially deprived areas faced significantly ...
The recommendation comes as school districts statewide grapple with budget deficits and calls grow louder for a big boost in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback